חדשות מהעולם

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June 30, 2010, after the market closes on Tuesday, September 7, 2010

Given Imaging (NASDAQ: GIVN) today announced that Mr. Homi Shamir, President and Chief Executive Officer, will present at the following investor conferences

Finland and Israel are jointly announcing the eighth Call for Proposals – FIT8 - for joint R&D projects, focusing on developing innovative products and applications in different technology areas

( Prolor a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR’s carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH.

PROLOR Biotech, Inc.a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company’s proprietary biobetter version of human growth hormone (hGH).

Effectively July 1, Roche Applied Science Industrial Business was relaunched under the name Roche Custom Biotech.

The ability to combat some age-related diseases, such as cancer and diabetes, may rest with scientists unlocking clues about the molecular and cellular processes governing aging

New research presented at the UK National Stem Cell Network Annual Science Meeting in Nottingham shows that adding fat to mouse stem cells grown in the lab affects their response to the signals that push them to develop into one or other of the main types of fat storage cells – subcutaneous (under the skin) or visceral (around the organs).

OctoPlus N.V. announced that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus' controlled release technology.

Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

Study published in The Journal of Molecular Diagnostics

CGEN-15001 also demonstrates pronounced delay of disease onset and significant decrease in disease symptoms

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma

The EverOn Touch System is the first FDA-cleared system that helps hospitals comply with patient turn protocols

REHOVOT, Israel & PHILADELPHIA, May 26, 2010 (BUSINESS WIRE) --Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces new data from two studies using the Company's miRview(TM) mets test to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP) will be presented in a poster session and in the abstract book at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting to be held at the McCormick Place Convention Center in Chicago from June 4-8, 2010.

PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that Chief Executive Officer Avri Havron and President Shai Novik will ring the opening bell at the New York Stock Exchange at 9:30 AM ET on Thursday, June 3, 2010.

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has commercially launched Gianvi (Drospirenone and Ethinyl Estradiol) Tablets, the Company's generic version of Bayer's Yaz® Tablets. Total sales of Yaz® Tablets were approximately $782 million in the United States, for the twelve months that ended December 31, 2009, based on IMS sales data.

Common Shares Already Listed on NYSE Amex Will Also List on the Tel Aviv Stock Exchange (TASE) Beginning May 27, 2010 under Ticker Symbol PBTH - - Company Anticipates Joining TASE’s TA-75, TA-100, Tel-Tech 15 and Biomed Indexes beginning June 13, 2010 -

REHOVOT, Israel & PHILADELPHIA, May 20, 2010 (BUSINESS WIRE) --Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the first quarter ended March 31, 2010, after the market closes on Wednesday, May 26, 2010.

IOptima's IOPtiMateTM's OT-135 laser based system, complies with EU CE Mark standards. This is the commercial model developed by IOPtima of the Israeli based Bio-Light group (TASE: BOLT), which enables the performance of a swift simplified, efficient and cost effective filtration procedure for the alleviation of Intra Ocular Pressure.

PROLOR Biotech, Inc., (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that PROLOR’s management will give a corporate presentation at the Rodman & Renshaw Sixth Annual Global Healthcare Conference

New drug target was predicted in silico through use of Compugen’s Monoclonal Antibody Targets Discovery Platform

However Tier Two Suppliers Capture Share from Smaller Competitors in Several Market Segments Revealed in Percepta Associates’ New Gene Expression Profiling Life Science Dashboard™ Market Research Report

Oramed Pharmaceuticals Inc. (OTCBB:ORMP), a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Canadian Patent Office has issued a Notice of Allowance for NexMed’s patent application entitled, “Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate

VIB and Cellectis, announced that they are going to collaborate on research into new approaches to cure haemophilia.

Corporate Overview and Status to be Presented in Webcast Today at 10 AM EDT

The Lupus Foundation of America (LFA) seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease

Collaboration agreement for the development and commercialization of CellDetect®, a novel screening and diagnosis technology of cervical cancer

Webcast to include updated company PowerPoint presentation

Darwin’s finches – some 14 related species of songbirds found on the Galapagos and Cocos Islands – will forever be enshrined in history for having planted the seeds of the theory of evolution through natural selection.

Teva Pharmaceutical Industries, Ltd. (NASDAQ:TEVA) announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies supporting the company's innovative central nervous system (CNS) portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

Highly dangerous Cryptococcus fungi love sugar and will consume it anywhere because it helps them reproduce.

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

The U.S. Patent and Trademark Office has granted U.S. Patent No. 7,670,832, reaching claims that apply to most of the real-time PCR instruments on the market.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar®

Nasdaq:GNVC - News) announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis.

Program focuses on beta cell replication and regeneration

Entelechon and Syntezza presented a new close cooperation they agreed upon recently. Effective immediately, Syntezza will distribute Entelechon's products and services on the Israeli market.

Pathway Genomics Inc., a U.S. based genetic testing company, responded to research released today at the American College of Cardiology annual meeting that found that the number of hospitalizations for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information for the patient was available to doctors prescribing the drug

Research Helps Focus Future Studies to Specifically Target the Series of Cellular Interactions That Cause the Body to Drop Its Guard

Teva Pharmaceutical Industries Ltd. announced today that its Board of Directors received a letter from Mr. Eli Hurvitz indicating that he wishes to be released from his duties at Teva in order to focus on his full recovery

A new study has found that one in three early-stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of recurrence. About one in four experienced distress when receiving their test results.

Company in Active Discussions with Several Large Pharmaceutical Companies for Potential Joint Venture/Licensing Partnerships for Its Cancer Vaccine Technology Platform

Zealand Pharma and PolyTherics Limited announced a research collaboration. Zealand has developed a number of peptide-based therapeutic candidates which are amenable to PEGylation

Merck reported initial pooled results from two Phase III studies of vicriviroc, its investigational HIV CCR5 receptor antagonist, in treatment-experienced HIV-infected patients, and said that based on these results it will not submit a New Drug Application (NDA) for vicriviroc in this patient population at this time.

After testing dozens of samples from marine mammals, University of Florida aquatic animal health experts say dolphins may be the ideal model for the study of cervical cancer in people

The "Vienna International Post-Graduate Program for Molecular Life Siences" (VIPS) supports scientists from their successful Ph.D. to establishing their own independent research group.

12 Feb 2010 - ExonHit Therapeutics S.A. announced that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog).

reports the successful completion of a clinical trial, aimed at identifying and diagnosing bladder cancer in biopsies via Zetiq's proprietary CellDetect® technology

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110),

Compugen announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders. CGEN-15001 is the extracellular region of a previously unknown membrane protein in the B7/CD28 family. The existence and potential utility of the newly discovered parent protein from which CGEN-15001 is derived was predicted in silico utilizing Compugen’s LEADS Platform and other proprietary algorithms.

Business wire: Rosetta Genomics today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs. The Company Now Has Six Issued U.S. Patents and 11 Allowed Patent Applications

Pluristem Therapeutics today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder. Results will be published in the journal Brain Research

By Daniel Matlis: The FDA is requesting $4.03 billion to promote and protect public health as part of the fiscal year 2011 budget. This represents a 23 percent increase over the agency's current $3.28 billion budget and includes a $146 million increase in budget authority and $601 million in industry user fees.

PRNewswire: Valtech Cardio announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financing of $17.8 million.

IOPtima the Israeli based Bio-Light group announces that after attending their first commercial conference in India where they exhibited, in conjunction with the Indian Care Group, their innovative OT-135 laser based system, known also as IOPtiMateTM, for the non invasive filtration treatment of Glaucoma, they received orders for the placement of the first 10 systems in leading ophthalmic centers in India..

Compugen Discovers Novel Protein for Treatment of Autoimmune Diseases CGEN-15001 demonstrates potent decrease in disease state in multiple sclerosis animal model Novel parent molecule was both discovered, and predicted to be member of the B7/CD28 co-stimulatory protein family, through use of in silico LEADS Platform

Monday, February 1, 2010, 8:30 – 16:00 Hadassah Hebrew University Hospital Ein Kerem, Jerusalem Participation is free of charge!

The growing level of innovative Israeli incubator projects focused on nutritional product development is behind a seasoned industry player’s decision to establish a consultancy aimed at taking these start-ups to the next level. Brenner pharma/food BD has recently been set up by the former vice president of marketing and business at Israeli ingredients supplier Solbar Industries, Gary Brenner.

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced today that it has closed the sale of its specialty pharmaceutical business to the sigma-tau Group ("sigma-tau"). Enzon is a biopharmaceutical company dedicated to the discovery and development of important medicines for patients with cancer and other life-threatening conditions. Enzon's business now consists of its royalties, Peg SN38, LNA and PEG technology platforms.

ALLEGAN, Mich. – Jan 27, 2010 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on March 16, 2010 to shareholders of record on February 26, 2010.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a Nov. 10, 2009, District Court decision that the Company’s generic version of Takeda’s Prevacid® (lansoprazole) SoluTab does not infringe U.S. Patent No. 5,464,632.

Procognia is pleased to announce that it has received Helsinki Committee approval from Sheba Hospital in Tel HaShomer to perform a diagnostic trial on human participants. The focus of the research is the correlation between glycosylated biomarkers in the peripheral blood stream and the presence of cancer and inflammatory diseases in the intestine

Dr Ludwin Monz to become new Chief Executive Officer after AGM 2010—Chief Executive Officer Dr Michael Kaschke to return to the Supervisory Board

European Medicines Agency (EMA) Waives Requirement to Test StemEx® in Paediatric Patients 17 Years of Age and Under

Jerusalem, Israel, January 14, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Moody's Investor services has upgraded the Company's rating to A3 from Baa1. Following this most recent upgrade, the rating outlook is now stable.

January 14, 2010—Fremont, CA —AMAX, North America’s leader in High Performance Computing, is partnering with NVIDIA to launch the Tesla™ Bio Workbench program to enable bio-physicists and computational chemists to push the boundaries of life science research

San Francisco, Calif. – January 14, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced that it has expanded its development pipeline to seven molecules with the advancement of two novel development candidates, which have been designated ACE-435 and ACE-661

(Augusta, GA and Elmsford, NY, January 13, 2010; 3D Mobile Imaging of the CSRA and AFP Imaging Corporation [OTC.AFPC.PK]) Dental practitioners in Georgia and South Carolina can now offer the latest technology and greatest convenience to their patients thanks to a new mobile dental radiology service. 3D Mobile Imaging of the CSRA is the only mobile NewTom Cone Beam 3D (CB3D) Imaging unit in the area to offer state-of the-art CB3D service allowing patients to be scanned at the dentist's office

ACU-4429 Slows the Visual Cycle and Represents New Approach to Treating Leading Cause of Blindness in People Over 50; No Therapy Currently Approved

LONDON - 12 January 2010 HaloSource, a leading clean water company, has signed an agreement with WAL (S.A.), the Swiss based international water filtration products company, for the use of HaloSource‟s revolutionary HaloPure® disinfection cartridges in WAL 's jug and pitcher products.

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti–EGFR Monoclonal Antibody Combination Sym004

Berkeley, CA—January 8, 2010, Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causingmutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors

(COPPELL, Texas) January 8, 2010 - Mannatech, Incorporated (NASDAQ: MTEX - News), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of a randomized, double-blind, placebo-controlled study that shows healthy middle-aged adults who took one teaspoon of Ambrotose® complex1 twice daily performed significantly better on memory tasks and were overall more positive in their mood.2 *

FQHC aims to create a medical home for its patients through the use of award-winning healthcare technology

Sets Goals of $31 Billion in Revenues and Non-GAAP Net Income of $6.8 Billion by 2015

New 5 mL Prepacked Columns For Protein Purification Reduce Processing Costs, Save Time, Ensure Consistent Performance

01/07/10 01:45 PM EST, Biovest International, Inc. (Other OTC: BVTI) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market

The Only Digital Pathology Platform Flexible Enough to Support Third-Party Image Analysis Tools

BRIDGEWATER, NJ – January 6, 2010 – Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer

MENLO PARK, Calif., January 5, 2009 - Geron Corporation (Nasdaq: GERN) today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

Potential First-in-class Oral Immune Response Modifier

Tampa, FL – January 4, 2010 -- Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that United Drug plc, a leading international provider of services to healthcare manufacturers and pharmaceutical retailers, will implement Pilgrim’s SmartSolve® solution to standardize its quality and compliance operations

D-Pharm Ltd (DPRM: TASE) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel.

Company completes Controlled Equity Offering with total sales of 4.1 million shares at weighted average price of $4.91 per share

Existence and utility of CGEN-671 predicted in silico through use of Compugen’s Monoclonal Antibody Targets Discovery Platform New Drug Target is splice variant of known cancer drug target

Tel Aviv, Israel, December 23, 2009 --- Compugen Ltd. (NASDAQ: CGEN) announced today that it has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer. The discovery process, which will be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer

Paris, France, December 23, 2009 -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing

Extension of solution suite provides advanced management of healthcare workforce across hospitals, long term care facilities and staffing agencies

Exeter, NH, December 21, 2009 – CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment